Genmab reported DKK748M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 5.69B 6B Sep/2026
argenx SE USD 1.24B 213M Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bayer EUR 9.92B 121M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Demant DKK 10.79B 1.16B Jun/2026
Exelixis USD 390.27M 10M Sep/2026
Fresenius Medical Care EUR 4.55B 229.7M Sep/2026
Genmab DKK 748M 77M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
GN Store Nord DKK 1.96B 156M Sep/2026
GRIFOLS EUR 1.65B 101M Sep/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Lakefront Biotherapeutics EUR 48.75M 6.87M Sep/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.97B 630M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
UCB EUR 2.96B 196M Dec/2025